Thank you for downloading the white paper.

Applying the Center for Medical Technology Policy’s (CMTP) Chain of Evidence for Clinical Utility to Prolaris, a Prognostic Prostate Cancer Test Developed by Myriad Genetic Laboratories

Genomic medicine has opened promising avenues for molecular diagnostic testing in health care. Ongoing challenges and debate exist, however, around evaluating molecular diagnostic tests for clinical use, coverage and reimbursement.

Download PDF